Advertisement
Advertisement

Contact Person

Julia Arndt, M.Sc.

Managing Editor

Phone: +49 (0)711 - 2 29 87 33
Fax: +49 (0)711 - 2 29 87 50
send an Email


Plasma-derived versus recombinant factor concentrates in PUPs: a never ending debate?

Journal: Hämostaseologie
ISSN: 0720-9355
Topic:

61. Jahrestagung der Gesellschaft für Hämostase- und Thromboseforschung e. V.
Progress in Haemostasis
From individual patients to pathophysiological insights

DOI: https://doi.org/10.5482/HAMO-16-10-0040
Issue: Hefte von 2017 (Vol. 37): Issue 1 2017 (1-88)
Pages: 53-57
Ahead of Print: 2016-11-23

Plasma-derived versus recombinant factor concentrates in PUPs: a never ending debate?

E. Berntorp (1)

(1) Centre for Thrombosis and Hemostasis, Lund University, Skane University Hospital, Malmö, Sweden

Keywords

Haemophilia, inhibitor, previously untreated patients, factor concentrate

Summary

Inhibitor development in haemophilia is a serious complication to treatment with factor concentrates. Since the advent of more pure products, especially developed using recombinant DNA technology, some studies have shown an increased incidence of inhibitors in previously untreated patients (PUPs) receiving recombinant products whereas plasma-derived concentrates sometimes have been claimed to have a protective role, probably due to the content of von Willebrand factor (VWF). In fact, experiments indicate that the VWF may block uptake of factor VIII into macrophages for further processing to the immune system. Also, a competition between VWF and inhibitor binding to the C2 domain of factor VIII has been suggested. Recently, large cohort and surveillance studies have created a vigorous debate about the role of product class for inhibitor development as results have been conflicting. The only randomised prospective study, the SIPPET study, was published in 2016, and substantiated previous reports claiming that plasma derived concentrates give less inhibitors in patients with severe haemophilia A, previously not exposed to factor VIII. The debate will continue.

You may also be interested in...

1.
Khan Kavakli1 , Mike Makris 2 , Bulent Zulfikar 3 , Elizabeth Erhardtsen4 , Zvi S. Abrams4 , Gili Kenet5 for the NovoSeven trial (F7HAEM-1510) investigators

Thromb Haemost 2006 95 4: 600-605

https://doi.org/10.1160/TH05-07-0510

2.

Online Supplementary Material

M. Biswas (1), G. L. Rogers (1), A. Sherman (1), B. J. Byrne (1), D. M. Markusic (1), H. Jiang (2), R. W. Herzog (1)

Thromb Haemost 2017 117 1: 33-43

https://doi.org/10.1160/TH16-05-0404

3.

C. E. Walsh (1), V. Jiménez-Yuste (2), G. Auerswald (3), S. Grancha (4)

Thromb Haemost 2016 116 Suppl. 1: S10-S17

https://doi.org/10.1160/TH16-01-0049